These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7874885)

  • 1. Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods.
    Jones RN
    Diagn Microbiol Infect Dis; 1994 Nov; 20(3):167-70. PubMed ID: 7874885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpretive criteria for DU-6859a disk diffusion tests using 5-micrograms disks.
    Jones RN; Johnson DM; Erwin ME
    Diagn Microbiol Infect Dis; 1994 Feb; 18(2):125-7. PubMed ID: 8062531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interpretive criteria for CI-960 (AM-1091, PD127391) disk diffusion tests using 5-microgram disks.
    Jones RN; Erwin ME; Barrett MS
    Diagn Microbiol Infect Dis; 1992; 15(4):379-81. PubMed ID: 1319303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
    Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
    Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of the new fluoroquinolone CP-99,219.
    Neu HC; Chin NX
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results.
    Jones RN; Barrett MS; Deguchi T
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):193-200. PubMed ID: 9327248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reevaluations of disk diffusion susceptibility testing interpretive criteria for lomefloxacin and norfloxacin using fluoroquinolone-resistant isolates.
    Cormican MG; Jones RN
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):227-30. PubMed ID: 7554807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin.
    Fuchs PC; Barry AL; Brown SD; Sewell DL
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):678-82. PubMed ID: 8894580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
    Kronvall G; Holst E
    Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers, and assessment of disk diffusion test interpretive criteria.
    Fuchs PC; Barry AL; Brown SD
    Diagn Microbiol Infect Dis; 2000 Dec; 38(4):243-53. PubMed ID: 11146251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
    Gooding BB; Jones RN
    Antimicrob Agents Chemother; 1993 Feb; 37(2):349-53. PubMed ID: 8043036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone.
    Jones RN; Erwin ME; Biedenbach DJ; Johnson DM; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Nov; 35(3):227-34. PubMed ID: 10626134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
    Fuchs PC; Barry AL; Brown SD
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifications for disk diffusion susceptibility testing criteria of clinafloxacin (CI-960, AM-1091, PD127371) and fleroxacin (Ro 23-6240, AM-833) following studies with a challenge panel of ciprofloxacin-resistant clinical isolates.
    Jones RN; Johnson DM
    Diagn Microbiol Infect Dis; 1995 Apr; 21(4):209-13. PubMed ID: 7554803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
    Kayser FH; Wüst J
    Eur J Clin Microbiol Infect Dis; 1991 Mar; 10(3):163-6. PubMed ID: 2060516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proposed quality control and interpretive criteria for disk diffusion susceptibility testing with enoxacin.
    Rudrik JT; Cavalieri SJ; Britt EM
    J Clin Microbiol; 1985 Mar; 21(3):332-4. PubMed ID: 3856570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
    Jones RN; Kugler KC; Erwin ME; Biedenbach DJ; Beach ML; Pfaller MA
    Diagn Microbiol Infect Dis; 1999 Apr; 33(4):247-53. PubMed ID: 10212751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.
    Barry AL; Fuchs PC; Allen SD; Tenover FC; Jorgensen JH; Reller LB
    J Clin Microbiol; 1995 Jan; 33(1):235-8. PubMed ID: 7699050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
    Fuchs PC; Barry AL; Jones RN; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
    Diagn Microbiol Infect Dis; 1987 Mar; 6(3):185-92. PubMed ID: 3471371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.